Disease · MONDO_0008114

obsessive-compulsive disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. obsessive-compulsive disorder. Diseases, record MONDO_0008114. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008114

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: obsessive-compulsive disorder; Open Targets
Open Targets ID: MONDO_0008114; Open Targets
Other names: Compulsive behaviors, OCD, Obsessive compulsive behavior, Obsessive compulsive behaviour, obsessive-compulsive disorder, susceptibility to; Open Targets
Disease Ontology: DOID:10933; Disease Ontology
MeSH: D009771; MeSH
NCI Thesaurus: C88411; NCI Thesaurus
Highest stage of its drugs: Approval, for 7 of its 73 drugs, from DailyMed and TTD; Open Targets

Drugs73

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLUVOXAMINE	CHEMBL814	Small molecule	Approval	TTD	7	6	6	Drugs and targets
SERTRALINE HYDROCHLORIDE	CHEMBL1709	Small molecule	Approval	DailyMed	5	1	1	Drugs and targets
FLUVOXAMINE MALEATE	CHEMBL1409	Small molecule	Approval	DailyMed	3	1	1	Drugs and targets
FLUOXETINE HYDROCHLORIDE	CHEMBL1201082	Small molecule	Approval	DailyMed	6	0	0	Drugs and targets
PAROXETINE HYDROCHLORIDE	CHEMBL6067650	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
PAROXETINE MESYLATE	CHEMBL1200609	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
CLOMIPRAMINE HYDROCHLORIDE	CHEMBL1200710	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CYCLOSERINE	CHEMBL771	Small molecule	Phase 3	ClinicalTrials.gov	10	9	9	Drugs and targets
SERTRALINE	CHEMBL809	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
SEROTONIN	CHEMBL39	Small molecule	Phase 3	ClinicalTrials.gov	6	6	0	Drugs and targets

1 to 10 of 73

See all 73 drugs

Targets75

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A4	Monoamine transporter	18	Monoamine transporter inhibitor; Serotonin transporter inhibitor; Sodium-dependent serotonin transporter releasing agent	Approval	https://conductscience.org/library/genes/6532	Drugs and targets
DRD2	D(2) dopamine receptor	6	D2-like dopamine receptor agonist; Dopamine D2 receptor antagonist; Dopamine D2 receptor partial agonist	Phase 3	https://conductscience.org/library/genes/1813	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	6	Glutamate [NMDA] receptor antagonist; Glutamate [NMDA] receptor negative allosteric modulator; Glutamate [NMDA] receptor subunit epsilon 1 antagonist	Phase 3	https://conductscience.org/library/genes/2903	Drugs and targets
HTR2A	5-hydroxytryptamine receptor 2A	6	Serotonin 2a (5-HT2a) receptor agonist; Serotonin 2a (5-HT2a) receptor antagonist	Phase 3	https://conductscience.org/library/genes/3356	Drugs and targets
SLC6A2	Monoamine transporter	6	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent	Phase 2	https://conductscience.org/library/genes/6530	Drugs and targets
GABRA1	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	5	GABA-A receptor; anion channel allosteric antagonist; GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 3	https://conductscience.org/library/genes/2558	Drugs and targets

1 to 10 of 75

See all 75 targets

Trials114

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 7 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01302080	Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)		941	2021-10-08	Obsessive Compulsive Disorder	SERTRALINE	Its record names the disease	ClinicalTrials.gov
NCT03299166	Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disorder	Phase 2/3	426	2023-06-02	Obsessive-Compulsive Disorder	TRORILUZOLE	Its record names the disease	ClinicalTrials.gov
NCT01404208	2/2 D-Cycloserine Augmentation of CBT for Pediatric OCD	Not applicable	206	2017-02-27	Obsessive-Compulsive Disorder	CYCLOSERINE	Its record names the disease	ClinicalTrials.gov
NCT02218736	Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a	Phase 2	163	2019-01-08	ANXIETY DISORDERS (or Anxiety and Phobic Neuroses)	ATICAPRANT	Its record names the disease	ClinicalTrials.gov
NCT01411774	D-cycloserine Augmentation of Cognitive Behavioral Therapy (CBT) for Pediatric Obsessive-compulsive Disorder (OCD)	Phase 3	142	2018-01-23	Obsessive-compulsive Disorder	CYCLOSERINE	Its record names the disease	ClinicalTrials.gov
NCT00389493	Risperidone or Cognitive-Behavioral Therapy for Improving Medication Treatment for Obsessive-compulsive Disorder	Not applicable	100	2014-04-25	Obsessive-Compulsive Disorder	RISPERIDONE	Its record names the disease	ClinicalTrials.gov
NCT00251303	Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders	Phase 2	78	2014-07-15	Obsessive-Compulsive Disorder, Autism Spectrum Disorder, Autism, Asperger Disorder, Developmental Disorder	RILUZOLE	Its record names the disease	ClinicalTrials.gov
NCT01813019	Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy	Phase 2	50	2016-07-21	Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses	MAVOGLURANT	Its record names the disease	ClinicalTrials.gov
NCT01281969	Intravenous Immunoglobulin for PANDAS	Phase 3	48	2020-03-17	Obsessive-Compulsive Disorder, Children, Anxiety Disorder, Autoimmune Disease, PANDAS	HUMAN IMMUNOGLOBULIN G	Its record names the disease	ClinicalTrials.gov
NCT01617083	Antibiotic Treatment Trial for the PANDAS/PANS Phenotype	Phase 2	47	2018-04-10	PANS, PANDAS, Obsessive Compulsive Disorder (OCD)	AZITHROMYCIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 114

See all 114 trials

Comparisons in its trials43

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Troriluzole - Randomization Phase vs Placebo - Randomization Phase: deaths from any cause	0 of 122	0 of 122	244	NCT03299166	Trial comparisons
Troriluzole - Randomization Phase vs Placebo - Randomization Phase: serious adverse events	0 of 122	0 of 122	244	NCT03299166	Trial comparisons
D-Cycloserine vs Sugar Pill: serious adverse events	0 of 70	0 of 72	142	NCT01404208	Trial comparisons
Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: deaths from any cause	0 of 72	0 of 70	142	NCT01411774	Trial comparisons
Cognitive-behavioral Therapy Plus Pill Placebo vs Cognitive-behavioral Therapy Plus D-cycloserine: serious adverse events	0 of 72	0 of 70	142	NCT01411774	Trial comparisons
CERC-501 vs Placebo: deaths from any cause	0 of 45	0 of 44	89	NCT02218736	Trial comparisons
CERC-501 vs Placebo: serious adverse events	0 of 45	0 of 44	89	NCT02218736	Trial comparisons
Oxytocin vs Placebo: deaths from any cause	0 of 34	0 of 33	67	NCT02671266	Trial comparisons
Oxytocin vs Placebo: serious adverse events	0 of 34	0 of 33	67	NCT02671266	Trial comparisons
Riluzole vs Placebo: serious adverse events	1 of 30	0 of 30	60	NCT00251303	Trial comparisons

1 to 10 of 43

See all 43 comparisons in its trials

Papers from its trials60

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
33972795	RESULT	1	PubMed
29100251	RESULT	1	PubMed
27249077	RESULT	1	PubMed
27046314	RESULT	1	PubMed
26674413	RESULT	1	PubMed
26104826	RESULT	1	PubMed
24356715	RESULT	1	PubMed
24026523	RESULT	1	PubMed
23783065	RESULT	1	PubMed
23525525	RESULT	1	PubMed

1 to 10 of 60

See all 60 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008114

GET https://conductscience.org/api/diseases/v1/MONDO_0008114/drugs?page=2

API reference For AI assistants